However, considering that ruxolitinib has many side effects such as thrombocytopenia, anemia, and neutropenia and shows a low binding affinity for DCLK1, the development of new inhibitors that are selective and potent for DCLK1 should be directed. The gene discussed is DCLK1; the disease is anemia (phenotype).